Details
Industries BiotechnologyMedicalTherapeuticsDiversity Spotlight Women FoundedHeadquarters Regions San Francisco Bay Area, Silicon Valley, West Coast Founded Date 2021 Founders Crystal Mackall, Nancy Goodman, Robbie Majzner Operating Status Active Last Funding Type Post-IPO Equity Also Known As Syncopation Life Sciences Legal Name CARGO Therapeutics, Inc.
Stock Symbol NASDAQ:CRGX Company Type For Profit
Contact Email info@cargo-tx.com
CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologous CARs
advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.
Products and Services
Product Name | Product Description |
---|---|